denileukin diftitox + dexamethasone

This drug is a **combination therapy** consisting of **denileukin diftitox**, a recombinant fusion protein that links interleukin-2 (IL-2) to diphtheria toxin, and **dexamethasone**, a synthetic glucocorticoid corticosteroid. **Denileukin diftitox** targets and binds to the high-affinity interleukin-2 receptor (CD25) expressed on malignant T-cells, delivering the diphtheria toxin intracellularly, leading to cell death. It is primarily used in the treatment of **cutaneous T-cell lymphoma (CTCL)** and other malignancies expressing the IL-2 receptor. **Dexamethasone** is included to reduce the risk and severity of infusion-related hypersensitivity reactions and capillary leak syndrome, and may potentially enhance expression of CD25 on T-cells, improving efficacy. The combination has been studied primarily in lymphoma and relapsed/refractory settings, where dexamethasone is administered as a premedication or concurrently with denileukin diftitox[5][7][3].